In Re Diet Drugs (Phentermine/Fenfluramine/Dexfenfluramine) Products Liability Litigation , 573 F. App'x 178 ( 2014 )


Menu:
  •                                                        NOT PRECEDENTIAL
    UNITED STATES COURT OF APPEALS
    FOR THE THIRD CIRCUIT
    _____________
    No. 13-4548
    _____________
    IN RE: DIET DRUGS (PHENTERMINE/FENFLURAMINE/DEXFENFLURAMINE)
    PRODUCTS LIABILITY LITIGIATION
    Ruth A. Sanders,
    Appellant
    _______________
    On Appeal from the United States District Court
    for the Eastern District of Pennsylvania
    (D.C. No. 99-cv-20593; MDL Nos. 11-md-1203 and 16-md-1203)
    District Judge: Hon. Harvey Bartle, III
    _______________
    Submitted Under Third Circuit LAR 34.1(a)
    July 11, 2014
    Before: RENDELL, CHAGARES, and JORDAN, Circuit Judges.
    (Filed: July 14, 2014)
    _______________
    OPINION OF THE COURT
    _______________
    JORDAN, Circuit Judge.
    Ruth Sanders appeals an order of the United States District Court for the Eastern
    District of Pennsylvania denying her recovery under the terms of the Diet Drug
    Nationwide Class Action Settlement Agreement (“Settlement Agreement”). We will
    affirm.
    I.     Background
    This appeal relates to the settlement of multi-district products liability litigation
    regarding the diet drugs Pondimin® and Redux®, previously sold by American Home
    Products Corporation (“AHP”). See In re Diet Drugs Prods. Liab. Litig., 
    543 F.3d 179
    ,
    180-81 (3d Cir. 2008). In November 1999, Wyeth, the successor-in-interest to AHP,
    joined plaintiffs’ representatives in the Settlement Agreement, which the District Court
    approved. See 
    id. at 181
    . Under the terms of the Settlement Agreement, Wyeth was
    required to contribute funds, placed in a trust, for the payment of claims. See 
    id. at 180
    .
    The resulting AHP Settlement Trust (the “Trust”), acting through its trustees and claims
    administrator, administers and reviews claims to determine the benefits, if any, that a
    class member is qualified to receive under the terms of the Settlement Agreement. See
    id.1
    Sanders,2 a class member, sought compensation benefits under the Settlement
    Agreement. She based her claim on an echocardiogram performed in 2002 after she had
    1
    In several prior decisions, we have provided a detailed description of the Diet
    Drugs litigation. See, e.g., In re Briscoe, 
    448 F.3d 201
    , 206-08 (3d Cir. 2006); In re Diet
    Drugs Prods. Liab. Litig., 
    401 F.3d 143
    , 147-48 (3d Cir. 2005); In re Diet Drugs Prods.
    Liab. Litig., 
    385 F.3d 386
    , 389-92 (3d Cir. 2004); In re Diet Drugs Prods. Liab. Litig.,
    
    282 F.3d 220
    , 225-29 (3d Cir. 2002). We will therefore limit our discussion to the
    essential facts of the instant appeal.
    2
    Sanders is one of three claimants who have appealed simultaneously through the
    same counsel, the others being Elizabeth Lassetter (Case No. 13-4730) and Tonya Marler
    (Case No. 13-4731). All three relied on the same attesting physician in submitting their
    claims; they appeal the same issue – whether there was a reasonable medical basis to
    conclude they all suffered from moderate mitral regurgitation; and they raise the same
    arguments. The briefs on appeal are almost identical, as are the District Court’s opinions
    2
    ingested Pondimin for 240 days. Having reviewed the echocardiogram, an attesting
    physician, Dr. Howard Brazil, attached an affidavit (the “Green Form”) to her claim, in
    which he stated that she has “moderate mitral regurgitation” (Trust Supp. App. at 19),
    meaning the heart valve separating her upper and lower heart chambers fails to close
    properly, causing leakage. Under the Settlement Agreement, moderate mitral
    regurgitation is one of the qualifying medical conditions for compensation.3 Upon initial
    review, the Trust’s auditing cardiologist agreed that there was a “reasonable medical
    basis”4 to support Dr. Brazil’s representations and that Sanders’s claim was potentially
    payable. (Trust Supp. App. at 34.)
    Unfortunately, the Trust was inundated with fraudulent claims that included
    manipulated echocardiogram test results. See In re Diet Drugs, 
    543 F.3d at
    182 n.4. In
    light of that problem, and during the pendency of Sanders’s claim, the Seventh
    Amendment to the Settlement Agreement was agreed to and implemented. The Seventh
    Amendment provided two options to claimants who had not yet received post-audit
    approval and whose claims indicated signs of material misrepresentation: either
    regarding each claimant. For efficiency’s sake, then, we designate this as the primary
    opinion, and our opinions regarding Lassetter’s and Marler’s appeals draw from it.
    3
    Sanders was also diagnosed with an “ejection fraction” of 50-60%. The District
    Court found no reasonable medical basis for any of those diagnoses, but Sanders only
    appealed its determination regarding mitral regurgitation. We likewise only address that
    issue.
    4
    Under the Settlement Agreement Audit Rules, a “reasonable medical basis” is
    the standard that an auditing cardiologist applies in determining the validity of a medical
    diagnosis serving as the basis for a claim. (Class Counsel Supp. App. at 125b.) See, e.g.,
    In re Diet Drugs Prods. Liab. Litig., 
    543 F.3d at 183-84
    .
    3
    participate in new procedures, including additional medical reviews of submitted
    evidence or opt out of the Settlement’s Seventh Amendment and have their claims re-
    audited “to determine whether there were any intentional material misrepresentations
    made in connection with the Claim.” (App. at A5.) Sanders’s claim fell within the scope
    of the Seventh Amendment, and she chose the latter option. On March 6, 2007, the Trust
    issued a determination letter rejecting Sanders’s claim based on substantial evidence of
    intentional material misrepresentation. The letter included a declaration of another
    auditing cardiologist, Dr. Joseph Kisslo, who, in addition to agreeing with the Trust’s
    ultimate determination of intentional misrepresentation, concluded that there was no
    reasonable medical basis for finding moderate mitral regurgitation based on Sanders’s
    echocardiogram.
    Sanders, disagreeing with that determination, submitted a Notice of Contest of
    Post Audit Determination pursuant to Audit Rule 18 of the Settlement Agreement. She
    attached a supplemental affidavit from Dr. Brazil, as well as affidavits from the owner of
    the company that performed the echocardiogram and a sonographer, all attesting that the
    echocardiogram was performed according to the Settlement Agreement’s criteria. After
    reviewing those additional materials, the Trust reaffirmed in a Final Post Audit
    Determination that it would deny Sanders compensation benefits, because of substantial
    evidence of intentional material misrepresentations.
    Sanders formally disputed the Trust’s Final Post Audit Determination, and the
    Trust subsequently applied to the District Court to require Sanders to show cause why her
    claim should be paid. The District Court issued a show-cause order to Sanders and
    4
    referred her claim to a Special Master, who in turn appointed a Technical Advisor, Dr.
    Gary Vigilante, to review the claim. Dr. Vigilante issued a Technical Advisor Report, as
    required by the Settlement Agreement. In the report, Dr. Vigilante agreed with Dr.
    Kisslo that there was no reasonable medical basis for Dr. Brazil’s finding of moderate
    mitral regurgitation. He also agreed that the echocardiogram study “was not conducted in
    a manner consistent with medical standards.” (Trust Supp. App. at 167.) Sanders
    responded to Dr. Vigilante, arguing that there could be no “intentional material
    misrepresentation” in connection with Sanders’s claim because four different
    cardiologists were able to render an opinion on the echocardiogram. (Trust Supp. App. at
    172.)
    The show-cause record, including Dr. Vigilante’s report and the parties’
    statements of the case, was then submitted to the District Court. After reviewing the
    record, the Court found that Sanders had failed to meet her burden of proving that a
    reasonable medical basis existed to support her claim. It declined to reach the
    misrepresentation issue. The Court thus affirmed the Trust’s denial of her claim.
    Sanders timely appealed.
    5
    II.    Discussion5
    On appeal, Sanders brings six arguments, only two of which warrant more than
    passing discussion: first, that the evidence in the record met the burden of proof for
    establishing a reasonable medical basis for Dr. Brazil’s Green Form, and, second, that the
    Court erred by deputizing the Technical Advisor with judicial power. Both arguments
    are unpersuasive.6
    The District Court’s determination was not an abuse of discretion. “The test is not
    what this court would have done under the same circumstances; that is not enough. We
    5
    The District Court had jurisdiction over all terms of the Settlement Agreement
    under 
    28 U.S.C. §§ 1332
     and 1407. We exercise jurisdiction over a final order of the
    District Court pursuant to 
    28 U.S.C. § 1291
    . “We review a District Court’s exercise of its
    equitable authority to administer and implement a class action settlement for abuse of
    discretion.” In re Diet Drugs Prods. Liab. Litig., 
    543 F.3d at
    184 n.10. An abuse of
    discretion may be found if the District Court’s decision “rest[s] on a clearly erroneous
    finding of fact, an errant conclusion of law or an improper application of law to fact.” 
    Id.
    (citation omitted) (internal quotation marks omitted).
    6
    Sanders’s arguments regarding due process and fraud, as well as those based on
    pretrial orders and the Settlement Agreement itself, are unfounded. The Settlement
    Agreement expressly authorized the District Court to deny a claim “[i]f the Court
    determines that there was no reasonable medical basis to support a material
    representation made by a physician in support of a Claim.” (Class Counsel Supp. App. at
    126b.) It also allowed the Court to direct “such additional audits and/or adopt such
    additional claims administration procedures as the Court deems appropriate.” (Id.) Thus,
    the Court was permitted to re-audit Sanders’s claim and rule on a reasonable medical
    basis as opposed to intentional misrepresentation, and Sanders was on notice of the
    Settlement Agreement setting forth the Court’s capabilities. Sanders’s cited, extra-circuit
    authority, In re Deepwater Horizon, Nos. 130315-16, -30329, -31220, 
    2014 WL 2118983
    (5th Cir. May 19, 2014), which she includes in a supplemental letter, is not applicable
    here; the Fifth Circuit determined that the claims adjustor in that case exceeded his
    authority by requiring claims to meet a condition for approval that the settlement
    agreement expressly removed from consideration, 
    id. at *1-2
    . As for fraud, the
    Settlement Agreement does not require the Trust or the Court to prove that cause of
    action in order to deny a claim.
    6
    must feel that only one order could have been entered on the facts.” In re Orthopedic
    Bone Screw Prods. Liab. Litig., 
    246 F.3d 315
    , 320 (3d Cir. 2001) (quotation marks
    omitted) (quoting In re Gypsum Antitrust Cases, 
    565 F.2d 1123
    , 1128 (9th Cir. 1977)).
    Sanders fails to show that the only conclusion that could be drawn from her
    echocardiogram is that she suffered from moderate mitral regurgitation. As the District
    Court noted, she failed to rebut the opinions of Dr. Vigilante and Dr. Kisslo on that issue.
    She merely stood on her own cardiologists’ affirmations, which only disagree with those
    findings. But disagreement, without more, does not foreclose contrary conclusions.7
    Because Sanders cannot demonstrate that the District Court’s determination was an abuse
    of discretion, her argument that she met her burden to show a reasonable medical basis
    for her condition fails.
    As to the issue concerning the Technical Advisor, the Settlement Agreement Audit
    Rules permit a Special Master to assign a Technical Advisor to review the record and to
    prepare a report to the District Court “setting forth his/her opinions regarding the issue(s)
    in dispute in the audit.” (App. at A932.) The Technical Advisor also “act[s] as a
    sounding board for the judge – helping the jurist to educate himself in the jargon and
    theory disclosed by the testimony and to think through the critical technical problems.”
    Reilly v. United States, 
    863 F.2d 149
    , 158 (1st Cir. 1988). After reviewing the District
    7
    Sanders erroneously argues that the District Court was bound by the opinion of
    the original auditing cardiologist, who found signs of moderate mitral regurgitation.
    However, we agree with the Court that “[s]imply because an undeserving claim has
    slipped through the cracks so far is no reason for this court to put its imprimatur on a
    procedure which may allow it to be paid. ... [W]e will not ignore the findings of other
    cardiologists simply because the claim has previously passed audit.” (App. at A15 n.10
    (first alteration in original) (citation omitted).)
    7
    Court’s memorandum opinion and the show-cause record, we are satisfied that the Court
    considered the entire record, not just what the Technical Advisor said. Nothing here
    indicates a simple “rubber stamping” of the Technical Advisor’s opinion. (Appellant’s
    Br. at 35.)
    III.   Conclusion
    For the foregoing reasons, we will affirm.
    8